Arcturus Therapeutics is trading at $10.50, up 10.06%, amid biotech-sector strength.
- No clear company-specific announcement surfaced for November 4; third-quarter results are scheduled for November 5, after market close.
- XBI was up 2.13% during the regular session, providing sector context rather than a company-specific catalyst.
- Broad U.S. indexes also rallied; available evidence points mainly to sector strength, not a confirmed direct cause.